HK1093223A1 - 使維他命 環氧化物還原酶基因的單核苷酸多態性與華法令劑量相關聯的方法和組合物 - Google Patents

使維他命 環氧化物還原酶基因的單核苷酸多態性與華法令劑量相關聯的方法和組合物

Info

Publication number
HK1093223A1
HK1093223A1 HK06114003.0A HK06114003A HK1093223A1 HK 1093223 A1 HK1093223 A1 HK 1093223A1 HK 06114003 A HK06114003 A HK 06114003A HK 1093223 A1 HK1093223 A1 HK 1093223A1
Authority
HK
Hong Kong
Prior art keywords
single nucleotide
vitamin
correlation
compositions
methods
Prior art date
Application number
HK06114003.0A
Other languages
English (en)
Inventor
Darrel W Stafford
Tao Li
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34393028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1093223(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of HK1093223A1 publication Critical patent/HK1093223A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HK06114003.0A 2003-09-23 2006-12-20 使維他命 環氧化物還原酶基因的單核苷酸多態性與華法令劑量相關聯的方法和組合物 HK1093223A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50552703P 2003-09-23 2003-09-23
PCT/US2004/031481 WO2005030039A2 (en) 2003-09-23 2004-09-23 Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage

Publications (1)

Publication Number Publication Date
HK1093223A1 true HK1093223A1 (zh) 2007-02-23

Family

ID=34393028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06114003.0A HK1093223A1 (zh) 2003-09-23 2006-12-20 使維他命 環氧化物還原酶基因的單核苷酸多態性與華法令劑量相關聯的方法和組合物

Country Status (13)

Country Link
US (6) US7687233B2 (zh)
EP (4) EP2380985B1 (zh)
JP (4) JP2007506433A (zh)
AT (1) ATE455174T1 (zh)
AU (2) AU2004275828B2 (zh)
CA (1) CA2539434C (zh)
DE (1) DE602004025157D1 (zh)
DK (2) DK2380985T3 (zh)
ES (2) ES2453895T3 (zh)
HK (1) HK1093223A1 (zh)
PL (1) PL1842920T5 (zh)
PT (1) PT2380985E (zh)
WO (1) WO2005030039A2 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
EP2189523B1 (en) * 2003-10-14 2012-01-04 Baxter International Inc. Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
CA2575878A1 (en) * 2004-08-02 2006-02-09 Novozymes A/S Creation of diversity in polypeptides
EP1809767B1 (en) * 2004-10-18 2011-09-07 University of Washington Methods and compositions for predicting response to warfarin
US7445896B2 (en) 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
CN101142322B (zh) * 2004-12-21 2011-09-21 中央研究院 用于预测华法令敏感性的基因变体
JP2008531026A (ja) * 2005-02-28 2008-08-14 バクスター・インターナショナル・インコーポレイテッド ビタミンk依存性タンパク質発現を改善するための、ビタミンkエポキシドレダクダーゼサブユニット1の組換え同時発現
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
CN101198696B (zh) * 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
US8500720B2 (en) * 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
PT1969127E (pt) 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
TW200808976A (en) * 2006-06-02 2008-02-16 Pharmigene Inc Warfarin dosage prediction
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP2280734B1 (en) 2008-04-24 2014-02-26 Cantab Biopharmaceuticals Patents Limited Factor ix conjugates with extended half-lives
US20110243958A1 (en) * 2008-10-15 2011-10-06 President And Fellows Of Harvard College Antimicrobial agents that target bacterial vkor
AU2010269072B9 (en) 2009-07-10 2014-09-18 Csl Limited Method of increasing the expression yield of vitamin K-dependent proteins
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
JP2012139232A (ja) * 2012-03-15 2012-07-26 Univ Of North Carolina At Chapel Hill 活性ビタミンk依存性タンパク質を生産するための方法及び組成物
JP2014221048A (ja) * 2014-06-16 2014-11-27 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンk依存性タンパク質を生産するための方法及び組成物
BR102015012334A2 (pt) * 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3485810T2 (de) 1983-05-27 1992-12-10 Texas A & M University Syst Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4770999A (en) 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンk依存性蛋白質のガンマカルボキシル化の増強
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
WO1991001372A1 (en) 1989-07-17 1991-02-07 New England Medical Center Hospitals, Inc. VITAMIN K-DEPENDENT η-CARBOXYLASE
EP0540650A1 (en) * 1990-07-23 1993-05-12 Zymogenetics, Inc. Gamma-carboxylase and methods of use
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5698765A (en) 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
JP3741447B2 (ja) 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−1遺伝子の機能が欠損したマウス
WO1994016101A2 (en) 1993-01-07 1994-07-21 Koester Hubert Dna sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
WO1995034679A2 (en) 1994-06-16 1995-12-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defects in drug metabolism
ZA965853B (en) 1995-07-13 1998-01-12 Du Pont Merck Pharma Asymmetric synthesis of r and s warfarin and its analogs.
DE19625049A1 (de) 1996-06-22 1998-01-02 Inst Pflanzengenetik & Kultur Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
AU2015799A (en) * 1997-12-24 1999-07-19 Immunex Corporation V201 dna and polypeptides
US5896337A (en) 1998-02-23 1999-04-20 Micron Technology, Inc. Circuits and methods for multi-level data through a single input/ouput pin
JP2002532056A (ja) * 1998-07-10 2002-10-02 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト輸送タンパク質相同体
WO2000030152A1 (en) * 1998-11-18 2000-05-25 Koninklijke Philips Electronics N.V. Luminescent material
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6453244B1 (en) * 2000-02-10 2002-09-17 Stanford University Detection of polymorphisms by denaturing high-performance liquid chromatography
US6492115B1 (en) 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
DE60137950D1 (de) 2000-10-02 2009-04-23 Novo Nordisk Healthcare Ag Verfahren zur herstellung vitamin-k-abhängiger proteine
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
EP1404702A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences Inc SEPARATE HUMAN PROTEINS
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP2189523B1 (en) * 2003-10-14 2012-01-04 Baxter International Inc. Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
EP1809767B1 (en) 2004-10-18 2011-09-07 University of Washington Methods and compositions for predicting response to warfarin
US7445896B2 (en) 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
CN101142322B (zh) 2004-12-21 2011-09-21 中央研究院 用于预测华法令敏感性的基因变体
WO2006067116A1 (en) 2004-12-21 2006-06-29 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
JP2008531026A (ja) 2005-02-28 2008-08-14 バクスター・インターナショナル・インコーポレイテッド ビタミンk依存性タンパク質発現を改善するための、ビタミンkエポキシドレダクダーゼサブユニット1の組換え同時発現
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
CN101198696B (zh) 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
WO2007065173A2 (en) 2005-12-02 2007-06-07 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
PT1969127E (pt) 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
TW200808976A (en) 2006-06-02 2008-02-16 Pharmigene Inc Warfarin dosage prediction
JP2009005240A (ja) * 2007-06-25 2009-01-08 Nec Tokin Corp 無線ネットワークシステムおよび無線ネットワーク通信方法

Also Published As

Publication number Publication date
WO2005030039A2 (en) 2005-04-07
DK2380985T3 (en) 2014-03-17
DK1842920T3 (da) 2010-05-03
EP1842920B1 (en) 2010-01-13
US20060240440A1 (en) 2006-10-26
JP2007506433A (ja) 2007-03-22
US8097410B2 (en) 2012-01-17
US7524665B2 (en) 2009-04-28
ES2339710T3 (es) 2010-05-24
JP2012161315A (ja) 2012-08-30
AU2004275828A1 (en) 2005-04-07
EP2336360A1 (en) 2011-06-22
JP2015180205A (ja) 2015-10-15
US7687233B2 (en) 2010-03-30
WO2005030039A3 (en) 2005-07-21
EP2380985A1 (en) 2011-10-26
JP5094920B2 (ja) 2012-12-12
US20070009950A1 (en) 2007-01-11
EP1670947B1 (en) 2015-04-01
DK1842920T4 (da) 2017-08-21
ATE455174T1 (de) 2010-01-15
EP2380985B1 (en) 2014-01-01
EP1842920B2 (en) 2017-06-21
PL1842920T3 (pl) 2010-06-30
ES2339710T5 (es) 2017-10-05
CA2539434C (en) 2014-03-18
JP2010268803A (ja) 2010-12-02
DE602004025157D1 (de) 2010-03-04
AU2010203318A1 (en) 2010-08-12
US20090215045A1 (en) 2009-08-27
US7482141B2 (en) 2009-01-27
EP1842920A1 (en) 2007-10-10
AU2004275828B2 (en) 2010-04-29
US8426128B2 (en) 2013-04-23
CA2539434A1 (en) 2005-04-07
AU2010203318B2 (en) 2012-07-12
EP1670947A2 (en) 2006-06-21
PT2380985E (pt) 2014-03-26
US20070190614A1 (en) 2007-08-16
EP1670947A4 (en) 2008-11-05
JP5840539B2 (ja) 2016-01-06
US7858318B2 (en) 2010-12-28
PL1842920T5 (pl) 2018-04-30
US20110124000A1 (en) 2011-05-26
US20090215061A1 (en) 2009-08-27
ES2453895T3 (es) 2014-04-08

Similar Documents

Publication Publication Date Title
HK1093223A1 (zh) 使維他命 環氧化物還原酶基因的單核苷酸多態性與華法令劑量相關聯的方法和組合物
TW200636075A (en) Detection of nucleic acid variation by cleavage-amplification method
AU2003241311A8 (en) Simple catalytic dna biosensors for ions based on color changes
HK1098792A1 (en) Base specific cleavage of methylation-specific amplification products in combination with mass analysis
ATE330038T1 (de) Nukleinsäure-biosensor
WO2002038806A3 (de) Nachweis von nukleinsäure-polymorphismen
WO2008034110A9 (en) Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors
AU2003226052A8 (en) Methods for detecting abnormally methylated nucleic acid in heterogeneous biological samples
WO2005073722A3 (en) Luminogenic and nonluminogenic multiplex assay
AU2003209127A8 (en) High-sensitivity real-time polymerase chain reaction for detection of nucleic acids
WO2003054166A3 (en) Nucleotide polymorphisms associated with osteoarthritis
WO2006044686A3 (en) Methods and compositions for predicting drug responses
EP1741793A4 (en) HYBRIDIZATION PROCESS
WO2007067557A3 (en) Methods for cyclic nucleotide determination
WO2005026389A3 (en) Ligation-based method of analysis of single nucleotide polymorphisms on genomic dna
WO2004009843A3 (de) Nachweis von mikroorganismen
WO2004099755A3 (en) Method of electrochemical detection of somatic cell mutations
WO2006065971A3 (en) Compositions and methods for polynucleotide amplification and detection
WO2002079512A3 (en) Method for detection and quantification of the fungus aspergillus fumigatus using quantitative pcr
EP1650300A4 (en) METHOD FOR ASSESSING THE RISK OF DRUG-INDUCED GRANULOCYTOPENIA
WO2005003388A3 (en) Fluorescence assays for nucleic acid polymerase activity
WO2004022784A3 (en) Strand specific detection and quantification
WO2006023768A3 (en) Methods and materials for detecting mutations in quasispecies having length polymorphism
EP1606389A4 (en) COMPOSITIONS AND METHODS FOR DETECTING POLYNUCLEOTIDE SEQUENCES
AU2003215600A1 (en) Increasing the sensitivity and specificity of nucleic acid chip hybridization tests

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200921